Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Public ClinicalTrials.gov record NCT00886743. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label study in which oprelvekin will be administered for the prevention of severe low blood platelet cell counts (cells in your blood that keep bleeding and clotting stable) in adults with cancer who are taking chemotherapy (anti-cancer drug) that has a side effect of blocking your bone marrow from making platelet cells. The purpose of this study is to learn more about the effects of the recommended dose of oprelvekin on the heart's electrical cycle.
Study identification
- NCT ID
- NCT00886743
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2009 (Type not available)
- Primary completion
- Dec 2015 (Actual)
- Completion
- Dec 2015 (Actual)
- Last update posted
- Apr 19, 2017
2009 – 2015
United States locations
- U.S. sites
- 14
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Santa Monica | California | 90403 | — |
| Sarcoma Oncology Center | Santa Monica | California | 90403 | — |
| Howard University | Washington D.C. | District of Columbia | 20060 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20060 | — |
| Montgomery Cancer Center | Mount Sterling | Kentucky | 40353 | — |
| Pfizer Investigational Site | Mount Sterling | Kentucky | 40353 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Pfizer Investigational Site | Canton | Ohio | 44718 | — |
| Gabrail Cancer Center Research | Dover | Ohio | 44622 | — |
| Pfizer Investigational Site | Dover | Ohio | 44622 | — |
| Pfizer Investigational Site | Middletown | Ohio | 45042 | — |
| Signal Point Clinical Research Center, LLC | Middletown | Ohio | 45042 | — |
| Pfizer Investigational Site | Laredo | Texas | 78041 | — |
| South Texas Research Alliance LLC. | Laredo | Texas | 78041 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00886743, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2017 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00886743 live on ClinicalTrials.gov.